- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| Do | Reviva Dives on Stock Offering | 1 | Baystreet.ca | ||
| REVIVA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Do | Reviva Pharmaceuticals holdings announces pricing of $10M public offering | 2 | Seeking Alpha | ||
| Do | Reviva preist öffentliches Angebot von 10 Millionen US-Dollar zu 0,50 US-Dollar pro Aktie | 1 | Investing.com Deutsch | ||
| Do | Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| Mi | Reviva Pharmaceuticals-Aktie fällt nach Ankündigung eines öffentlichen Angebots | 4 | Investing.com Deutsch | ||
| Mi | Reviva Pharmaceuticals stock falls after announcing public offering | 1 | Investing.com | ||
| Mi | Reviva Pharmaceuticals announces public offering of common stock | 1 | Investing.com | ||
| Mi | Reviva Pharmaceuticals announces public offering; shares down nearly 15% | 1 | Seeking Alpha | ||
| Mi | Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering | 1 | GlobeNewswire (USA) | ||
| 06.06. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 02.06. | Reviva reports positive year-long schizophrenia drug study | 2 | Investing.com | ||
| 02.06. | Reviva Pharmaceuticals: Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia | 250 | GlobeNewswire (Europe) | - Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms - - Generally well-tolerated with low rates of adverse events and discontinuation... ► Artikel lesen | |
| 30.05. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 24.05. | Benchmark hält 14 US-Dollar Kursziel für Reviva Pharmaceuticals-Aktie aufrecht | 2 | Investing.com Deutsch | ||
| 20.05. | Reviva stock target cut to $3 on cash concerns, retains Buy rating | 4 | Investing.com | ||
| 15.05. | Reviva Pharmaceuticals GAAP EPS of -$0.13 | 1 | Seeking Alpha | ||
| 15.05. | Reviva Pharmaceuticals: Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights | 94 | GlobeNewswire (Europe) | - 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment - - Full data set from RECOVER OLE... ► Artikel lesen | |
| 09.04. | Reviva Pharmaceuticals target cut to $14 by Benchmark | 2 | Investing.com | ||
| 03.04. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 26,610 | +1,26 % | Kriegserklärung an Pharmaindustrie!? Bayer, Novo Nordisk und Geheimtipp PanGenomic Health | Hat US-Gesundheitsminister Robert F. Kennedy Jr. der traditionellen Pharmaindustrie den Krieg erklärt? In diese Richtung äußerte sich jedenfalls der ehemalige Trump-Pressesprecher und heutige Podcaster... ► Artikel lesen | |
| PFIZER | 20,775 | +0,24 % | Depot Verdoppler mit Künstlicher Intelligenz: Novo Nordisk, PanGenomic Health und Pfizer zünden 2025 den Profit-Turbo | Lauf BlackRock Health Sciences steht der globale Gesundheitssektor 2025 vor einem beispiellosen Aufschwung. Nach Jahren der Volatilität durch die Pandemie soll die Branche jetzt die höchsten Gewinnzuwächse... ► Artikel lesen | |
| ROCHE | 282,50 | +0,78 % | Ihre wichtigsten Termine: Alle Analysten-Augen auf: Kingfisher, Roche, Prosus, New Work und Zooplus! | © Foto: Uwe Anspach/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr... ► Artikel lesen | |
| VIATRIS | 7,730 | 0,00 % | Viatris Reports Positive Data From Presbyopia Study | WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS), Thursday announced positive top-line results from VEGA-3, evaluating MR-141 in patients with presbyopia, the progressive loss of the ability to focus... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 4,502 | -1,83 % | Green Thumb Industries Reports First Quarter 2025 Results | CHICAGO and VANCOUVER, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. ("Green Thumb" or the "Company") (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer... ► Artikel lesen | |
| CASSAVA SCIENCES | 1,575 | +0,45 % | Cassava Sciences, Inc.: Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development | AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a clinical-stage biotechnology company focused on developing novel, investigational... ► Artikel lesen | |
| NEWRON PHARMACEUTICALS | 7,250 | +0,42 % | Newron Pharmaceuticals - Next stage unlocked for evenamide | Newron has announced receipt of regulatory clearance to conduct its Phase III programme for evenamide (ENIGMA-TRS), taking it one step closer to the market. It will comprise two separate trials: ENIGMA-TRS... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 1,845 | +0,74 % | Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical | Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology
Accelerating multiple late-stage cancer therapies... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 3,170 | +5,14 % | Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades | Omnicom cross-agency collaboration to drive technology-led, innovative launch strategy Partnership brings together promising science, top-tier talent, and advanced technologies to enable a faster... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 7,224 | -0,41 % | Aurinia Pharmaceuticals Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| KAZIA THERAPEUTICS | 6,435 | 0,00 % | Kazia Therapeutics Limited: Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC) | SYDNEY, June 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company pioneering next-generation oncology therapeutics... ► Artikel lesen | |
| LIPOCINE | 3,230 | 0,00 % | Lipocine Inc.: Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression | Phase 3 Top Line Results Expected Q2 2026
SALT LAKE CITY, June 26, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging... ► Artikel lesen | |
| ALLERGY THERAPEUTICS | 0,074 | +2,07 % | Allergy Therapeutics - Allergy Therapeutics presents findings at EAACI | ||
| SUNSHINE BIOPHARMA | 1,470 | 0,00 % | Sunshine Biopharma Inc.: Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market | FORT LAUDERDALE, FL / ACCESS Newswire / June 11, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of... ► Artikel lesen | |
| MERCK KGAA | 113,00 | +1,21 % | MilliporeSigma and "Abbott Elementary" Inspire Students' Curiosity With Hands-On STEM | NORTHAMPTON, MA / ACCESS Newswire / June 25, 2025 / Between September 2024 and April 2025, MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, teamed up with... ► Artikel lesen |
Das Unternehmen REVIVA PHARMACEUTICALS HOLDINGS INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,358 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVIVA PHARMACEUTICALS HOLDINGS INC finden Sie auf Wallstreet Online.